

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
AIMOVIG® (erenumab-aooe)	Neuroscience	Pediatric Migraine	Monoclonal Antibody	3
DESCRIPTION Aimovig® inhibits the calcitonin gene-related peptide receptor (CGRP-R). It is being investigated in a Phase 3 study for prevention of chronic and episodic migraine in pediatric patients.				
BLINCYTO® (blinatumomab)	Hematology/Oncology	Pediatric Acute Lymphoblastic Leukemia	BiTE® Antibody Construct	3
DESCRIPTION BLINCYTO® is an anti-CD 19 x anti-CD3 BiTE® (bispecific T cell engager) antibody construct. It is being investigated in a Phase 3 study for acute lymphoblastic leukemia (ALL) in pediatric patients at first relapse.				
EVENITY® (romosozumab-aqqg)	Bone	Male Osteoporosis	Monoclonal Antibody	3
DESCRIPTION EVENITY® is a humanized monoclonal antibody that inhibits the action of sclerostin. It is being investigated in a Phase 3 study for male osteoporosis.				
IMLYGIC® (talimogene laherparepvec)	Hematology/Oncology	Metastatic Melanoma	Oncolytic Immunotherapy	3
DESCRIPTION IMLYGIC® is an oncolytic immunotherapy derived from herpes simplex virus type 1 (HSV-1). It is being investigated in a Phase 3 study as a combination treatment with Merck & Company, Inc.'s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with mid- to late-stage metastatic melanoma.				
KYPROLIS® (carfilzomib)	Hematology/Oncology	Multiple Myeloma	Small Molecule	3
DESCRIPTION KYPROLIS® is a small molecule proteasome inhibitor. It is being investigated in the Phase 3 A.R.R.O.W-2 study for weekly dosing in combination with lenalidomide and dexamethasone for relapsed multiple myeloma.				

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 12, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
	Hematology/Oncology	Multiple Myeloma	Small Molecule	3
	DESCRIPTION KYPROLIS® is a small molecule proteasome inhibitor. It is being investigated in the Phase 3 CANDOR study in combination with dexamethasone and DARZALEX® (daratumumab) compared to KYPROLIS® and dexamethasone alone.			
NPLATE® (romiplostim)	Hematology/Oncology	Chemotherapy-Induced Thrombocytopenia	Peptibody	3
	DESCRIPTION Nplate® is a thrombopoietin (TPO) receptor agonist. It is being investigated in a Phase 3 study for early chemotherapy-induced thrombocytopenia (CIT).			
OMECAMTIV MECARBIL	Cardiovascular	Heart Failure	Small Molecule	3
	DESCRIPTION Omecamtiv mecarbil is a small molecule selective cardiac myosin activator, also called a myotrope, which directly targets the contractile mechanisms of the heart. It is being investigated in Phase 3 studies for the potential treatment of heart failure with reduced ejection fraction (HFrEF).			
	ADDITIONAL INFORMATION Omecamtiv mecarbil is being developed under a collaboration between Amgen and Cytokinetics, with funding and strategic support from Servier.			
OTEZLA® (apremilast)	Inflammation	Behcet's Disease	Small Molecule	3
	DESCRIPTION Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated in a Phase 3 study for oral ulcers associated with Behcet's disease.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 12, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
	Inflammation	Pediatric Plaque Psoriasis	Small Molecule	3
	DESCRIPTION Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated in a Phase 3 study for pediatric plaque psoriasis.			
	Inflammation	Mild to Moderate Plaque Psoriasis	Small Molecule	3
	DESCRIPTION Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated in a Phase 3 study for mild to moderate plaque psoriasis.			
	Inflammation	Genital Psoriasis	Small Molecule	3
	DESCRIPTION Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated in a Phase 3 study for severe genital psoriasis.			
	PARSABIV® (etelcalcetide)	Nephrology	Pediatric Secondary Hyperparathyroidism	Peptide
DESCRIPTION Parsabiv® is a peptide that binds to the calcium-sensing receptor. It is being investigated in a Phase 3 study in pediatric patients with secondary hyperparathyroidism and chronic kidney disease receiving hemodialysis.				
PROLIA® (denosumab)	Bone	Pediatric Glucocorticoid-Induced Osteoporosis	Monoclonal Antibody	3
	DESCRIPTION Prolia® is a monoclonal antibody that inhibits RANK ligand. It is being investigated in a Phase 3 study in pediatric patients with glucocorticoid-induced osteoporosis (GIOP).			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 12, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
REPATHA® (evolocumab)	Cardiovascular	Hypercholesterolemia	Monoclonal Antibody	3
	DESCRIPTION Repatha® is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). It is being investigated in the Phase 3 VESALIUS – CV study in high-risk cardiovascular disease patients without prior heart attack or stroke.			
	Cardiovascular	Pediatric Familial Hypercholesterolemia	Monoclonal Antibody	3
	DESCRIPTION Repatha® is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). It is being investigated in a Phase 3 study in pediatric patients with familial hypercholesterolemia (FH).			
TEZEPelumab	Inflammation	Severe Asthma	Monoclonal Antibody	3
	DESCRIPTION Tezepelumab is a human monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP). It is being investigated in a Phase 3 study for severe asthma.			
	ADDITIONAL INFORMATION In September 2018, we announced that the FDA granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma without an eosinophilic phenotype. Tezepelumab is being developed in collaboration with AstraZeneca plc.			
	Inflammation	Atopic Dermatitis	Monoclonal Antibody	2
DESCRIPTION Tezepelumab is a human monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated in a Phase 2 study for atopic dermatitis.				
ADDITIONAL INFORMATION Tezepelumab is being developed in collaboration with AstraZeneca plc.				

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 12, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
	Inflammation	Chronic Obstructive Pulmonary Disease	Monoclonal Antibody	2
	<p>DESCRIPTION Tezepelumab is a human monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated in a Phase 2 study for chronic obstructive pulmonary disease.</p> <p>ADDITIONAL INFORMATION Tezepelumab is being developed in collaboration with AstraZeneca plc.</p>			
ABP 798 (biosimilar rituximab)	Hematology/Oncology	Non-Hodgkin's Lymphoma	Monoclonal Antibody	3
	<p>DESCRIPTION ABP 798, a biosimilar candidate to rituximab (Rituxan[®]/Mabthera[®]), is an anti-CD20 monoclonal antibody. It is being investigated in a Phase 3 study for non-Hodgkin's lymphoma.</p> <p>The reference product primary indications are non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis.</p> <p>ADDITIONAL INFORMATION Amgen is developing ABP 798 in collaboration with Allergan.</p>			
	Inflammation	Rheumatoid Arthritis	Monoclonal Antibody	3
	<p>DESCRIPTION ABP 798, a biosimilar candidate to rituximab (Rituxan[®]/Mabthera[®]), is an anti-CD20 monoclonal antibody. It is being investigated in a Phase 3 study for rheumatoid arthritis.</p> <p>The reference product primary indications are non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis.</p> <p>ADDITIONAL INFORMATION Amgen is developing ABP 798 in collaboration with Allergan.</p>			
ABP 959 (biosimilar eculizumab)	Hematology/Oncology	Paroxysmal Nocturnal Hemoglobinuria	Monoclonal Antibody	3
	<p>DESCRIPTION ABP 959, a biosimilar candidate to eculizumab (Soliris[®]), is a monoclonal antibody that specifically binds to the complement protein C5. It is being investigated in a Phase 3 study for paroxysmal nocturnal hemoglobinuria (PNH).</p> <p>The reference product primary indications are paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).</p>			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 12, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
AMG 510	Hematology/Oncology	Solid Tumors	Small Molecule	2
	DESCRIPTION AMG 510 is a KRAS ^{G12C} small molecule inhibitor. It is being investigated in a Phase 2 study for non-small cell lung and colorectal cancers.			
ROZIBAFUSP ALFA (formerly AMG 570)	Inflammation	Systemic Lupus Erythematosus	Bispecific Antibody	2
	DESCRIPTION Rozibafusp alfa is a bispecific antibody-peptide conjugate that targets BAFF and ICOS ligand. It is being investigated in a Phase 2 study for systemic lupus erythematosus.			
AMG 714 / PRV-015	Inflammation	Celiac Disease	Monoclonal Antibody	2
	DESCRIPTION AMG 714 is a human monoclonal antibody that binds to IL-15. It is being investigated in a Phase 2 study for celiac disease. ADDITIONAL INFORMATION AMG 714 is being developed in collaboration with Provention Bio, Inc., where it is identified as PRV-015.			
AMG 119	Hematology/Oncology	Small Cell Lung Cancer	CAR T	1
	DESCRIPTION AMG 119 is a DLL3 CAR T (chimeric antigen receptor T cell) cellular therapy. It is being investigated in a Phase 1 study for small-cell lung cancer.			
AMG 160	Hematology/Oncology	Prostate Cancer	BiTE [®] Antibody Construct	1
	DESCRIPTION AMG 160 is a half-life extended anti-PSMA x anti-CD3 BiTE [®] (bispecific T cell engager) antibody construct. It is being investigated in a Phase 1 study for prostate cancer.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 12, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.



PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
AMG 171	Cardiovascular	Obesity	Fusion Protein	1
	DESCRIPTION AMG 171 is a GDF15-Fc fusion protein being investigated in a Phase 1 study as an anti-obesity treatment.			
AMG 176	Hematology/Oncology	Hematology	Small Molecule	1
	DESCRIPTION AMG 176 is an intravenous small molecule inhibitor of MCL-1. It is being investigated in a Phase 1 study for hematologic malignancies.			
AMG 199	Hematology/Oncology	Metastatic gastric and gastroesophageal junction cancer.	BiTE® Antibody Construct	1
	DESCRIPTION AMG 199 is a MUC17 targeting half-life extended) BiTE® (bispecific T cell engager) antibody construct. It is being investigated in a Phase 1 study for metastatic gastric and gastroesophageal junction cancer.			
AMG 212	Hematology/Oncology	Prostate Cancer	BiTE® Antibody Construct	1
	DESCRIPTION AMG 212 is an anti-PSMA x anti-CD3 BiTE® (bispecific T cell engager) antibody construct. It is being investigated in a Phase 1 study for prostate cancer.			
AMG 330	Hematology/Oncology	Acute Myeloid Leukemia	BiTE® Antibody Construct	1
	DESCRIPTION AMG 330 is an anti-CD33 x anti-CD3 BiTE® (bispecific T cell engager) antibody construct. It is being investigated in a Phase 1 study for acute myeloid leukemia.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 12, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
AMG 397	Hematology/Oncology	Hematology	Small Molecule	1
	DESCRIPTION AMG 397 is an oral small molecule inhibitor of MCL-1. It is being investigated in a Phase 1 study for hematologic malignancies.			
AMG 404	Hematology/Oncology	Solid Tumors	Monoclonal Antibody	1
	DESCRIPTION AMG 404 is a human anti-PD-1 monoclonal antibody being investigated as a treatment for patients with solid tumors. It is being developed in a Phase 1 study for use in combination with other Amgen oncology portfolio molecules.			
AMG 420	Hematology/Oncology	Multiple Myeloma	BiTE® Antibody Construct	1
	DESCRIPTION AMG 420 is an anti-BCMA x anti-CD3 BiTE® (bispecific T cell engager) antibody construct. It is being investigated in a Phase 1 study for multiple myeloma.			
AMG 424	Hematology/Oncology	Multiple Myeloma	XmAb® Antibody	1
	DESCRIPTION AMG 424 is a bispecific anti-CD38 x anti-CD3 T cell-recruiting antibody (XmAb® antibody) being investigated in a Phase 1 study for multiple myeloma.			
AMG 427	Hematology/Oncology	Acute Myeloid Leukemia	BiTE® Antibody Construct	1
	DESCRIPTION AMG 427 is a half-life extended anti-FLT3 x anti-CD3 BiTE® (bispecific T cell engager) antibody construct. It is being investigated in a Phase 1 study for acute myeloid leukemia.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 12, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
AMG 430	Inflammation	Respiratory Disease	Monoclonal Antibody	1
	DESCRIPTION AMG 430 is an anti-Jagged-1 monoclonal antibody being investigated in a Phase 1 study for respiratory diseases.			
AMG 506	Hematology/Oncology	Solid Tumors	DARPin [®] protein	1
	DESCRIPTION AMG 506 is a multi-specific FAP x 4-1BB-targeting DARPin [®] biologic under investigation as a treatment for patients with solid tumors. It is being developed for use in combination with other Amgen oncology portfolio molecules. ADDITIONAL INFORMATION AMG 506 (also known as MP0310) is being developed in collaboration with Molecular Partners AG. DARPin [®] is a registered trademark owned by Molecular Partners AG.			
AMG 562	Hematology/Oncology	Non-Hodgkin's Lymphoma	BiTE [®] Antibody Construct	1
	DESCRIPTION AMG 562 is a half-life extended anti-CD19 x anti-CD3 BiTE [®] (bispecific T cell engager) antibody construct. It is being investigated in a Phase 1 study for non-Hodgkin's lymphoma.			
EFAVALEUKIN ALFA (formerly AMG 592)	Inflammation	Inflammatory Disease	Fusion Protein	1
	DESCRIPTION Efavaleukin alfa is an IL-2 mutein Fc fusion protein. It is being investigated in a Phase 1 study for rheumatoid arthritis, systemic lupus erythematosus and graft versus host disease.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 12, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
AMG 594	Cardiovascular	Heart Failure	Small Molecule	1
	<p>DESCRIPTION AMG 594 is a cardiac troponin activator. It is being investigated in a Phase 1 study for heart failure.</p> <p>ADDITIONAL INFORMATION AMG 594 was discovered under a joint research program conducted between Amgen and Cytokinetics.</p>			
AMG 596	Hematology/Oncology	Glioblastoma	BiTE® Antibody Construct	1
	<p>DESCRIPTION AMG 596 is an anti-EGFRvIII x anti-CD3 BiTE® (bispecific T cell engager) antibody construct. It is being investigated in a Phase 1 study for glioblastoma.</p>			
AMG 673	Hematology/Oncology	Acute Myeloid Leukemia	BiTE® Antibody Construct	1
	<p>DESCRIPTION AMG 673 is a half-life extended anti-CD33 x anti-CD3 BiTE® (bispecific T cell engager) antibody construct. It is being investigated in a Phase 1 study for acute myeloid leukemia.</p>			
AMG 701	Hematology/Oncology	Multiple Myeloma	BiTE® Antibody Construct	1
	<p>DESCRIPTION AMG 701 is a half-life extended anti-BCMA x anti-CD3 BiTE® (bispecific T cell engager) antibody construct. It is being investigated in a Phase 1 study for multiple myeloma.</p>			
AMG 757	Hematology/Oncology	Small Cell Lung Cancer	BiTE® Antibody Construct	1
	<p>DESCRIPTION AMG 757 is a half-life extended anti-DLL3 x anti-CD3 BiTE® (bispecific T cell engager) antibody construct. It is being investigated in a Phase 1 study for small-cell lung cancer.</p>			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 12, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.



PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
AMG 890	Cardiovascular	Cardiovascular Disease	siRNA	1
	DESCRIPTION AMG 890 is a small interfering RNA (siRNA) that targets lipoprotein(a), also known as Lp(a). It is being investigated in a Phase 1 study for cardiovascular disease.			

[‡] In addition to the above programs, AMJEVITA™/AMGEVITA™, MVASI™, and KANJINTI™ have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA™ has been approved by the FDA.

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 12, 2020 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.